Table 3 Summary of treatment-emergent adverse events (TEAEs) for the pooled safety population
Eptinezumab | Placebo | ||||||
|---|---|---|---|---|---|---|---|
Patients, n (%) | 1000 mga (n = 81) | 300 mgb (n = 823) | 100 mgb (n = 701) | 30 mgb (n = 341) | 10 mgc (n = 130) | All (N = 2076) | (N = 791) |
Any TEAE | 46 (56.8) | 467 (56.7) | 366 (52.2) | 184 (54.0) | 74 (56.9) | 1137 (54.8) | 414 (52.3) |
Any study-drug–related TEAEd | 16 (19.8) | 124 (15.1) | 92 (13.1) | 42 (12.3) | 21 (16.2) | 295 (14.2) | 74 (9.4) |
Any serious TEAE | 2 (2.5) | 17 (2.1) | 11 (1.6) | 4 (1.2) | 1 (0.8) | 35 (1.7) | 11 (1.4) |
Any TEAE leading to study drug discontinuation | 0 | 19 (2.3) | 9 (1.3) | 12 (3.5) | 0 | 40 (1.9) | 8 (1.0) |
Any TEAE leading to interruption of study-drug infusion | 0 | 19 (2.3) | 11 (1.6) | 10 (2.9) | 0 | 40 (1.9) | 6 (0.8) |